Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
Alimera Appoints Maggie A. Pax to Its Board of Directors
04:30pm, Wednesday, 08'th Nov 2023
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Thursday, 26'th Oct 2023
Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.75 per share a year ago.
Alimera Sciences Reports Third Quarter 2023 Results
07:00am, Thursday, 26'th Oct 2023
ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partner
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
08:00am, Wednesday, 11'th Oct 2023
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
08:00am, Tuesday, 03'rd Oct 2023
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partner
Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript
02:08pm, Thursday, 10'th Aug 2023
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibs
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
10:00am, Thursday, 10'th Aug 2023
Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.
Alimera Sciences Reports Second Quarter 2023 Results
07:30am, Thursday, 10'th Aug 2023
ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partner
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
11:43am, Wednesday, 02'nd Aug 2023
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce
Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum
09:52am, Thursday, 08'th Jun 2023
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks tha
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
10:49am, Thursday, 01'st Jun 2023
Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
Alimera (ALIM) Completes Enrollment in Eye Disease Study
11:17am, Thursday, 25'th May 2023
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock
09:53am, Tuesday, 23'rd May 2023
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stock
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
01:46pm, Friday, 19'th May 2023
Alimera Sciences ALIM announced acquiring additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq from EyePoint Pharmaceuticals, Inc. Yutiq is indicated to treat chronic non-infe
How to Develop a Penny Stocks Trading Mentality
06:00am, Friday, 19'th May 2023
Can these tips help you become a better penny stocks trader? The post How to Develop a Penny Stocks Trading Mentality appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.c
